Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
- PMID: 31366588
- DOI: 10.1136/bmjebm-2019-111231
Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
Keywords: cardiology; myocardial infarction.
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical